GoAI
Get started
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc.

TARA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.85

−$0.05 · -1.28%

Aug 21, 4:00 PM ET

Pre-market

$3.81

−$0.04 · -1.04%

Aug 24, 4:39 AM ET

TARA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

35

Expensive

Momentum

33

Weakening

Sentiment

43

Mixed

Risk resilience

30

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jesse Shefferman
Listed since
Oct 22, 2014
Employees
46

Market position

Day range

Current $3.85

52-week range

Current $3.85

Open
$3.905
Previous close
$3.90
Volume
238.44K
0.38× average
Average volume
629.81K
Average daily volume
Market cap
216.39M USD
Beta
1.49
Market reference 1
50-day average
$4.0194
-4.21% below average
200-day average
$5.1849
-25.75% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
182.02M USD
P/E (TTM)
-2.83×
P/B (TTM)
1.46×
P/S (TTM)
0×
EV / EBITDA
-3.19×
Earnings yield
-25.16%
Free cash flow yield
-24.73%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-29.24%
Return on assets
-27.42%
Return on invested capital
-32.31%

Financial health

Debt / equity
0.02×
Current ratio
14.58×
Altman Z-score
5.66
Piotroski F-score
1 of 9

Financial statements

Income trends

Operating income

−64.55M USD-31.32%

Net income

−57.44M USD-28.80%
Income trends across reported periods−37.76M USD−48.41M USD−59.07M USD−69.73M USDOperating income, FY2021: −47.49M USDOperating income, FY2022: −67.06M USDOperating income, FY2023: −43.61M USDOperating income, FY2024: −49.15M USDOperating income, FY2025: −64.55M USDNet income, FY2021: −47.25M USDNet income, FY2022: −65.95M USDNet income, FY2023: −40.42M USDNet income, FY2024: −44.6M USDNet income, FY2025: −57.44M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −47.49M USD. Operating income FY2022 −67.06M USD. Operating income FY2023 −43.61M USD. Operating income FY2024 −49.15M USD. Operating income FY2025 −64.55M USD. Net income FY2021 −47.25M USD. Net income FY2022 −65.95M USD. Net income FY2023 −40.42M USD. Net income FY2024 −44.6M USD. Net income FY2025 −57.44M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold362K USD—341K USD——
Gross profit−362K USD—−341K USD——
Research and development42.63M USD31.7M USD24.79M USD16.81M USD21.09M USD
Selling, general, and administrative21.92M USD17.45M USD18.62M USD20.74M USD26.4M USD
Operating expenses64.19M USD49.15M USD43.27M USD67.06M USD47.49M USD
Interest income6.33M USD4.14M USD2.73M USD1.11M USD237K USD
Interest expense———1.14M USD1.74M USD
Depreciation and amortization362K USD332K USD341K USD248K USD117K USD
Operating income−64.55M USD−49.15M USD−43.61M USD−67.06M USD−47.49M USD
Net income−57.44M USD−44.6M USD−40.42M USD−65.95M USD−47.25M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 2 misses, 1 met estimate
Average EPS surprise
+12.79%
11 comparable reports
Latest EPS result
-0.36
Estimate -0.33 · Miss by 10.53%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.25-0.37-0.49-0.61Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 5, 2025: actual -0.48, estimate -0.57, surprise +15.79%, Beat. Q2 2025, reported May 8, 2025: actual -0.29, estimate -0.47, surprise +38.30%, Beat. Q3 2025, reported Aug 11, 2025: actual -0.35, estimate -0.43, surprise +18.60%, Beat. Q4 2025, reported Nov 10, 2025: actual -0.31, estimate -0.39, surprise +20.51%, Beat. Q1 2026, reported Mar 10, 2026: actual -0.37, estimate -0.32, surprise -15.62%, Miss. Q2 2026, reported May 13, 2026: actual -0.31, estimate -0.36, surprise +13.89%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.36, estimate -0.326, surprise -10.53%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.36, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$12.00

211.69% upside
Past 12 months12-month forecastHigh $12.00Average $12.00Low $12.00

Rating distribution

6 ratings
Strong buy00%
Buy6100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

4 institutions
JP MorganmaintainOverweight
GuggenheimmaintainBuy

TARA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TARA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
6.5M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
5.24M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.3M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
1.84M
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.15M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
694.77K
Weight
0.05%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
564.95K
Weight
0.01%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Vanguard U.S. Momentum Factor ETF logoVanguard U.S. Momentum Factor ETFVFMO
Market value
542.36K
Weight
0.03%
AUM
1.8B USD
Expense ratio
0.13%
Price / 1D
$232.52+0.68%

Continue in GoAI

Research TARA

research.disclaimer